TITLE: A genomic variant of *ALPK2* is associated with increased liver fibrosis risk in HIV/HCV coinfecting women

Author Names and Affiliations: Alec T. McIntosh,¹ Renhuizi Wei,¹ Jaeil Ahn,² Brad E. Aouizerat,³ Seble G. Kassaye,⁴ Michael H. Augenbraun,⁵ Jennifer C. Price,⁶ Audrey L. French,⁷ Stephen J. Gange,⁸ Kathryn M. Anastos,⁹ and Radoslav Goldman^{1,10,11,*}

¹Department of Oncology, Georgetown University, Washington, DC

²Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center, Washington, DC

³Bluestone Center for Clinical Research, College of Dentistry, New York University, New York, NY

⁴Department of Infectious Diseases, Georgetown University Medical Center, Washington, DC

⁵Department of Medicine, Division of Infectious Diseases, State University of New York, Downstate Medical Center, Brooklyn, NY

⁶Department of Medicine, Division of Liver Diseases, University of California San Francisco, San Francisco, CA

⁷Department of Internal Medicine, Division of Infectious Disease, Stroger Hospital of Cook County, Chicago, IL

⁸Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD

⁹Departments of Medicine and Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY

¹⁰Department of Biochemistry and Molecular & Cell Biology, Georgetown University Medical Center, Washington, DC

¹¹Clinical Translational Glycoscience Research Center, Georgetown University Medical Center, Washington, DC

***Corresponding Author Information:** Radoslav Goldman, Georgetown University, Department of Oncology, NRB E207, 3970 Reservoir Road NW, Washington, DC 20057. Phone: 202-687-9868; E-mail: rg26@georgetown.edu

ABSTRACT

HIV coinfection is associated with more rapid liver fibrosis progression in hepatitis C (HCV) infection. Recently, much work has been done to improve outcomes of liver disease and to identify targets for pharmacological intervention in coinfecting patients. In this study, we analyzed clinical data of 1,858 participants from the Women's Interagency HIV Study (WIHS) to characterize risk factors associated with changes in the APRI and FIB-4 surrogate measurements for advanced fibrosis. We assessed 887 non-synonymous single nucleotide variants (nsSNV) in a subset of 661 coinfecting participants for genetic associations with changes in liver fibrosis risk. The variants utilized produced amino acid substitutions that either altered an N-linked glycosylation (NxS/T) sequon or mapped to a gene related to glycosylation processes. Seven variants were associated with an increased likelihood of liver fibrosis. The most common variant, *ALPK2* rs3809973, was associated with liver fibrosis in HIV/HCV coinfecting patients; individuals homozygous for the rare C allele displayed elevated APRI (0.61, 95% CI, 0.334 to 0.875) and FIB-4 (0.74, 95% CI, 0.336 to 1.144) relative to those coinfecting women without the variant. Although warranting replication, *ALPK2* rs3809973 may show utility to detect individuals at increased risk for liver disease progression.

INTRODUCTION

The emergence of highly active antiretroviral therapy has transitioned the once acutely fatal human immunodeficiency virus (HIV) infection to a chronic disease. However, the longer survival of persons living with HIV infection presents a new set of morbidities and increased risk for mortality [1-3]. Due to common modes of transmission, those infected

with HIV are at higher risk of contracting hepatitis C virus (HCV). Accelerated progression of liver disease in HIV/HCV coinfectd patients compared to those with HCV monoinfection is well documented and liver disease has become a leading cause of non-AIDS related death in coinfectd individuals [4,5]. The pathogenesis of liver disease in coinfectd individuals is multifactorial [6]. Despite substantial progress in identifying risk factors for liver disease progression in coinfectd persons, our understanding of risk factors remains incomplete, with genomic factors among those that remain ill-defined. Even with the emergence of direct-acting HCV antivirals, the ability of these agents to regress fibrosis upon HCV clearance remains unclear [7] and the cost of treatment is often inaccessible to at-risk populations [8]. Taken together, these considerations document that liver fibrosis remains a challenge in coinfectd and HCV monoinfectd patients. In this study, we examined the impact of non-synonymous single nucleotide variants (nsSNV) affecting N-glycosylation both directly at the NxS/T sequons of proteins and indirectly through the enzymes and lectins of glycosylation-related pathways.

Glycosylation is one of the most common and structurally diverse protein modifications and affects protein synthesis, structure, and function [9]. Glycosylation enzymes or the glycoproteins they produce are involved in immune surveillance and host-pathogen interactions [10,11] as well as in the progression of viral liver disease [12]. To elucidate the impacts of glycosylation on the pathogenesis of fibrosis in HIV/HCV coinfectd patients, we focused on nsSNV affecting the NxS/T sequons required for the attachment of N-glycans to proteins and thus the potential to change the number of

glycans on the protein surface [13,14]. The Women's Interagency HIV Study (WIHS) is a longitudinal natural history study of HIV infection that features a sufficient number of HIV/HCV coinfecting participants and biomarkers of liver disease to evaluate the impact of risk factors for liver disease progression [15], including genetic risk factors [16-18]. Given its longitudinal cohort design, the Fibrosis-4 Index (FIB-4)[19] and the AST to Platelet Ratio Index (APRI)[20] were collected in the WIHS cohort as noninvasive surrogate measures of hepatic fibrosis. These measures were used in lieu of serial tissue biopsy as the means with which to evaluate genetic risk factors in HIV/HCV coinfection [21]. A set of 887 nsSNV were extracted from a genome-wide association study performed in the WIHS cohort. Of these, 278 nsSNV produce an amino acid substitution that alters the potential glycosylation of target proteins by altering the number of N-glycans decorating a protein, which we analyzed in relation to surrogate biomarkers of liver fibrosis. Given that previous work demonstrated that genetic variation in glycosylation-related enzymes and lectins can alter kinetics and binding affinities respectively, the remaining 609 of 887 nsSNV were glycosylation-related proteins evaluated in relation to surrogate biomarkers of liver fibrosis in coinfecting participants [22,23].

METHODS

Study Population

The WIHS is a multicenter prospective study of the natural history of HIV infection among women with or at risk for HIV-infection in the United States. Established in 1994, a total of 4,982 women (3,677 HIV-seropositive) have been enrolled. At semi-annual

visits, participants completed socio-demographic and medical questionnaires, laboratory testing, and a limited physical examination. Data included in this analysis include age, race and ethnicity, continuous clinical measures of liver fibrosis (APRI and FIB-4), plasma HIV RNA viral titer, HCV infection status (at all visits), and HCV viral titer (at baseline only) [24]. HCV status was defined as “positive” when participants had both positive HCV antibody and detectable HCV RNA at their baseline visit. Those that were defined as “negative” had no detectable HCV antibody upon testing. Self-reported race and ethnicity was used to define four groups: “White” (non-Hispanic), “African American” (non-Hispanic), “Hispanic”, or “Other”. In addition to self-reported race and ethnicity, genomic estimates of ancestry were derived using principle component analysis of ancestry informative genetic markers [25].

Genotyping

Genotype data in WIHS was generated from genomic DNA from peripheral blood mononuclear cells using the Infinium Omni2.5 BeadChip (Illumina, San Diego, CA, USA) [24]. Of the 10,141 genes (602 glycogene + 9,539 NxS/T-containing genes) known to exist in the human genome, data on 1,029 nsSNVs (698 glycogene + 331 NxS/T) spanning 660 genes (349 glycogene + 311 NxS/T) from 2,120 WIHS participants were available for analysis [13]. Of these 2,120 women, 262 participants were either HCV antibody positive in the absence of detectable HCV RNA (N=156) or HCV serostatus was never assessed at baseline (N=106) and therefore excluded (Supplemental Figure 1). Of the 331 NxS/T nsSNVs, 44 were mono-allelic (non-polymorphic) and therefore excluded. Among the 287 nsSNVs that remained, missing

genotypes across 1,858 patients were imputed with the most common genotype for each nsSNVs (mean participants imputed per nsSNV $\pm$ SD= 5 $\pm$ 6.04). Of the 698 glycogene nsSNVs, 75 were monomorphic and excluded. Among the 623 nsSNVs that remained, missing genotypes across 1,858 patients were imputed with the most common genotype for each nsSNV (mean participants imputed per nsSNV $\pm$ SD= 5 $\pm$ 6.21). A minor allele frequency (MAF) threshold $\geq$ 0.001 ($\geq$ 0.1%) was applied using the MAFs of the coinfecting population (N=661) to further isolate SNVs sufficiently frequent to allow for statistical analysis. Using this method, an additional 9 NxS/T and 14 glycogenes were eliminated from analysis. After applying all exclusion criteria, clinical and genotype (887 glycogene [609 nsSNV, 278 NxS/T nsSNV] spanning 564 genes) data were available for 1,858 women (Supplemental Figure 1). The nsSNV reference sequence identifiers (rsID), major (or common) and minor (or rare) alleles, and MAF across serotypes are provided as supplementary tables for the NxS/T (Supplemental Table 1) and glycogene (Supplemental Table 2) nsSNVs utilized in our analysis.

Serologic Markers of Fibrosis

Fibrosis-4 Index (FIB-4) and the AST to Platelet Ratio Index (APRI) were used as measures of hepatic fibrosis as described in previous literature [21]. For the FIB-4 index, scores $<$ 1.45 and $>$ 3.25 indicate a high negative and a high positive predictive value for advanced fibrosis respectively [19]. For APRI, scores $<$ 0.5 have a high negative predictive value for liver disease while scores $>$ 0.7 and $>$ 2 indicate a high positive predictive value for moderate and severe hepatic fibrosis respectively [20].

Genetic polymorphisms were independently analyzed against each continuous surrogate index (i.e., APRI, FIB-4) at baseline to identify variants with stronger associations that would manifest across both current clinical diagnostic resources.

Statistical Analysis

For descriptive summaries, continuous variables were summarized using means and standard deviations while categorical variables were summarized using frequency counts and percentages. HIV and HCV RNA status were categorized into 4 serostatus groups: both HIV/HCV noninfected, HIV monoinfected, HCV monoinfected, and HIV/HCV coinfectd. Distributions of APRI, FIB-4, and HIV RNA viral load among the four serostatus groups were summarized using descriptive statistics and were compared using chi-square analyses or one-way Analysis of Variance (ANOVA). APRI and FIB-4 scores used for analysis were obtained at baseline visits (pre-2003) at a time prior to the broad use of HCV therapy. For each variant from the 278 NxS/T and 609 glycogene nsSNV that met inclusion criteria, a separate multiple variable linear regression model was constructed for the HIV/HCV coinfectd patient population for continuous APRI and FIB-4 outcomes. Explanatory variables included each variant, age, race and ethnicity, HIV viral load, and HCV viral load. Model results were indistinguishable when adjusted for HCV viral load or HCV status. Genomic estimates of racial and ethnicity were estimated using principle component analysis of 185 ancestry informative markers (SNV) selected to differentiate major racial and ethnic groups in the cohort (i.e., European, African, Hispanic)[25]. The first three principle components (PC1, PC2, PC3) were utilized to adjust for genomic estimates of race and ethnicity in the

139 aforementioned linear regression models. HIV and HCV viral load were normalized
140 using $\log_2(x+1)$ transformation. The false discovery rate (FDR) was used to account for
141 multiple testing (i.e., 887 linear regression each for FIB-4 and APRI). All reported p -
142 values are two-sided, and SNV associations with $FDR < 0.05$ were considered
143 statistically significant. To investigate whether the impact of SNV varies across the four
144 serogroups, we examined SNV*serostatus interactions and computed 95% confidence
145 intervals for each SNV genotype*serostatus configuration. Statistical analyses were
146 performed using SAS *version* 9.4 (SAS Institute, Cary, NC, USA) and R *version* 3.3 (R
147 Core Team, Vienna, Austria).

149 RESULTS

150 Of the 75% of women who were HIV seropositive (1386 of 1858), 52% ($n=725$) were
151 HIV monoinfected and 48% ($n=661$) were HIV/HCV coinfectd (Table 1).
152 The remaining 25% of women ($N=472$) were HCV/HIV noninfected and 22% ($N=104$)
153 were HCV monoinfected. The proportion of non-Hispanic African-Americans differed
154 significantly between the four serogroups ($P < 0.001$) (Table 1). Post-hoc contrasts
155 indicate that, in comparison to non-Hispanic African Americans, Hispanics were less
156 likely ($OR=0.66$ [95% CI, 0.499 to 0.881], $P_{FDR}=0.03$) and non-Hispanic Whites were
157 more likely ($OR=1.82$ [95% CI, 1.272 to 2.609], $P_{FDR}=0.006$) to be in the coinfectd
158 serogroup as compared to the HIV monoinfected group. HCV-infected women were
159 older on average ($P < 0.001$) than those not infected with the virus (Table 1). Post-hoc
160 contrasts indicate that in comparison to the noninfected serogroup, older subjects were
161 more likely to be monoinfected with HIV ($OR=1.08$ [95% CI, 1.059 to 1.100], P_{FDR}

Table 1. Baseline population characteristics of patients by serostatus

Variable	Noninfected	Monoinfected	Monoinfected	Coinfected	
	HIV ⁻ /HCV ⁻	HIV ⁺ /HCV ⁻	HIV ⁻ /HCV ⁺	HIV ⁺ /HCV ⁺	
Levels	N=368	N=725	N=104	N=661	<i>P</i>
Age at BL, mean± SD	29.6 ± 8.0	33.2 ± 7.4	39.2 ± 7.2	39.8 ± 6.2	<0.0001
HIV load, mean± SD[†]	0	11.3 ± 4.4	0	14.0 ± 3.8	<0.0001
HCV load, mean± SD[†]	0	0	19.1 ± 3.3	20.5 ± 2.8	<0.0001
Race, N(%)					
Non-Hispanic White	47 (12.8)	69 (9.5)	13 (12.5)	111 (16.8)	<0.0001
Non-Hispanic A-A	205 (55.7)	400 (55.2)	63 (60.6)	416 (62.9)	
Hispanic	101 (27.5)	227 (31.3)	23 (22.1)	123 (18.6)	
Other	15 (4.1)	29 (4.0)	5 (4.8)	11 (1.7)	
APRI, N(%)					
<0.5	367 (99.7)	633 (87.3)	64 (61.5)	267 (40.4)	<0.0001
0.5-0.7	0 (0.0)	39 (5.4)	13 (12.5)	135 (20.4)	
>0.7	1 (0.3)	53 (7.3)	27 (26.0)	259 (39.2)	
FIB-4, N(%)					
<1.45	366 (99.5)	657 (90.6)	79 (76.0)	336 (50.8)	<0.0001
1.45-3.25	2 (0.5)	59 (8.1)	20 (19.2)	255 (38.6)	
>3.25	0 (0.0)	9 (1.2)	5 (4.8)	70 (10.6)	

Percentages based off columns.

[†]Viral loads are log₂ transformed (copies/mL)

Abbreviations: BL, Baseline; A-A, African-American.

<0.001), monoinfected with HCV (OR=1.21 [95% CI, 1.172, to 1.252], P_{FDR} <0.001) or
 coinfectd (OR=1.22 [95% CI, 1.197 to 1.252], P_{FDR} <0.001). Distribution of the APRI
 and FIB-4 fibrotic indexes, stratified by their clinically relevant cutoffs, also differed
 between the groups (P <0.001) (Table 1). Six pairwise comparisons of mean liver scores
 were performed between designated serogroups for each fibrosis metric (Figure 1). On
 average, coinfectd participants had higher APRI and FIB-4 measures when compared

168 to the HCV monoinfected population (APRI, 0.36, 95% CI, 0.064 to 0.651; FIB-4, 0.78,
169 95% CI, 0.375 to 1.184) and the HIV monoinfected population (APRI, 0.64, 95% CI,
170 0.487 to 0.786; FIB-4, 1.19, 95% CI, 0.984 to 1.397) (Figure 1). All other comparisons
171 between serogroups were found to be statistically significant (95% confidence interval)
172 except the mean APRI scores for noninfected vs. HIV monoinfected (-0.15, 95% CI, -
173 0.325 to 0.031) and HIV monoinfected vs. HCV monoinfected (-0.28, 95% CI, -0.571 to
174 0.012) which follow the expected trend but do not achieve statistical significance (Figure
175 1).

Figure 1. Mean liver fibrosis scores for each viral serotype. The mean APRI and FIB-4 scores at baseline visit + SD are shown for 1,858 women stratified by definitive viral serostatus. The number of patients (n) for each viral serostatus are indicated in Table 1. Pairwise comparisons of liver outcomes were performed for all viral-serotype group-comparisons within each liver metric. Only those comparisons not significant (*ns*) were labeled as such.

Utilizing the larger cohort for race and age adjustment helped to ensure that we had the population size to account for the impact of these variables on liver fibrosis. Whereas the first principle component of the PCA of genomic markers of ancestry (PC1) appeared to adequately differentiate African-Americans (non-Hispanic), Hispanics, and Whites (non-Hispanic) (Figure 2A), we took a conservative approach and included the first three principle components (PC1, PC2, PC3). Although adjusting for race/ethnicity using self-report identified the same genetic associations, we opted to employ the 3 PCs to better account for confounding that can occur with self-reported race and ethnicity. For example, many participants self-reporting as “Hispanic” or “Other” in the coinfectd subgroup present with a genetic background more consistent with the African-American (non-Hispanic) and White (non-Hispanic) clusters (Figure 2B).

Figure 2. Genomic Estimates of Race/Ethnicity using Principle Component Analysis. The 1,858 WIHS participants utilized in this study were stratified using 185 ancestral SNV markers from across the genome. PC1 and PC2 are depicted above. Genomic estimates of race and ethnicity were compared to reported race and ethnicity (A) and the distribution of HIV/HCV coinfectd participants of focus are displayed (B).

187 After adjustment for multiple testing, seven nsSNV mapping to separate genes met the
 188 *a priori* criterion of $P_{FDR} < 0.05$ for at least one of the biomarkers of liver fibrosis (Table
 189 2). Of these, only rs52828316 (*MAN2A2*) was significant by P_{FDR} for both indices. For all
 190 nsSNV, two copies of the minor allele (i.e., minor allele homozygotes) was associated
 191 with increases in APRI and/or FIB-4 (Table 2). Because it was the only variant
 192 sufficiently frequent to result in all three genotypic groups (i.e., major allele

Table 2. Baseline screen of multiple linear regression models

Model Fit (N= 661)		SNV + Age + PC1-3 + HIV Load + HCV Load [†]						Study Sample MAF
Outcome		APRI			FIB-4			
SNV	Alleles (N)	Estimate	<i>P</i>	<i>P</i> _{FDR}	Estimate	<i>P</i>	<i>P</i> _{FDR}	
rs3809973 <i>ALPK2</i> (K829N) [‡]	CC (154) AC (321) AA (186)	0.61 0.10 0	<0.01 0.39	<0.01	0.74 0.15 0	<0.01 0.40	0.08	0.48
rs17035120 <i>GLT8D2</i> (A37T) [‡]	TT (4) TC (81) CC (576)	2.00 -0.03 0	<0.01 0.84	0.42	3.77 0.16 0	<0.01 0.48	0.05	0.07
rs1800450 <i>MBL2</i> (G54D)	AA (6) AG (66) GG (589)	1.52 -0.32 0	<0.01 0.06	0.15	3.28 -0.42 0	<0.01 0.10	0.01	0.06
rs77452813 <i>MCOLN2</i> (V20I)	TT (2) TC (50) CC (609)	3.40 -0.13 0	<0.01 0.50	0.08	5.90 -0.16 0	<0.01 0.58	0.01	0.04
rs52828316 <i>MAN2A2</i> (R1039H)	AA (2) AG (42) GG (617)	7.55 -0.24 0	<0.01 0.24	<0.01	6.43 -0.30 0	<0.01 0.33	<0.01	0.03
rs2228015 <i>CCR7</i> (M7V)	TC (20) TT (641)	1.02 0	<0.01	0.08	1.75 0	<0.01	0.01	0.02
rs1800472 <i>TGFB1</i> (T263I)	TC (13) CC (648)	1.77 0	<0.01	<0.01	1.26 0	0.02	0.66	0.01

Bold Indicates Significant *P* Values.

[†] Multiple Linear Regression of each SNV adjusted for Age, Race (PC1-PC3), HIV and HCV Load.

Single Letter Amino Acid Abbreviation and Position of Resulting Substitution.

[‡]Potential Gain or Loss of an NxS/T Caused by Substitution.

Abbreviations: PC, Principle Component; NxS/T, N-linked Glycosylation Sequon; SNV, Single Nucleotide Variant; MAF, Minor Allele Frequency, FDR, False Discovery Rate.

193 homozygotes, heterozygotes, minor allele homozygotes), *ALPK2* rs3809973 was
194 evaluated further in relation to hepatic fibrosis among the four viral serogroups.

195 In order to see if the *ALPK2* variant's tentative association with increased liver fibrosis in
196 coinfecting women was preferentially impacted by the effects of either virus, we
197 analyzed each genotype of the *ALPK2* variant across all viral serostatuses utilized in the
198 cohort. For the *ALPK2* rs3809973, HIV/HCV coinfecting participants who were
199 homozygous for the minor allele had significantly higher mean APRI and FIB-4 scores
200 relative to the coinfecting participants homozygous for the major allele (APRI, 0.61, 95%
201 CI, 0.334 to 0.875; FIB-4, 0.74, 95% CI, 0.336 to 1.144) and compared to those HCV
202 mono-infected participants homozygous for the minor allele (APRI, 0.79, 95% CI, 0.370
203 to 1.200; FIB-4, 1.24, 95% CI, 0.820 to 1.650) (Figure 3A,3B). Evaluation of the
204 association of *ALPK2* rs3809973 with APRI and FIB-4 by racial and ethnic group (i.e.,
205 non-Hispanic African-American, non-Hispanic Caucasian, Hispanic)
206 revealed similar patterns of association with one exception in non-Hispanic African-
207 American where no difference by genotypic group was observed with FIB-4 (data not
208 shown). The heterozygotes of coinfecting individuals displayed no significant increases
209 in APRI or FIB-4 relative to the coinfecting major allele homozygotes (APRI, 0.10, 95%
210 CI, -0.128 to 0.332; FIB-4, 0.15, 95% CI, -0.195 to 0.492). These coinfecting population
211 findings for the *ALPK2* nsSNV (rs3809973) are against a background of similar CD4⁺ T-
212 cell percentage, measured relative to other leukocyte types, and detectable HIV viral
213 loads at baseline (Figure 3C,3D). HIV mono-infected participants homozygous for the
214 minor allele displayed significantly increased FIB-4 (0.45, 95% CI, 0.028 to 0.879)

Figure 3. rs3809973 (ALPK2) impact on APRI and FIB-4 Outcomes. Mean baseline APRI (A) and FIB-4 (B) score with 95% confidence interval shown for the allele pairs of each serotype (Total N=1,858). The number of samples representing each genotype for the respective serogroups is displayed as follows: homozygous for the major allele (green), heterozygous (orange), and homozygous for the minor allele (blue). Comparisons were shown, for reference, relative to the major allele homozygote of the noninfected serogroup. ANOVA was used to compare relative CD4⁺ T-cell percentages (C) or HIV/HCV viral loads (D) between the genotypes of each serogroup. No significant differences are denoted by *ns*. Asterisks indicate two-sided P-values below 0.05 (*) and 0.01 (**) respectively.

scores relative to noninfected participants homozygous for the minor allele, but the finding was not significant for the same comparison using APRI (0.00, 95% CI, -0.422 to 0.429) (Figure 3A, 3B). For the HIV monoinfected genotype, a slight significant difference in the CD4⁺ T-cell percentage ($P=0.007$) accompanied this FIB-4 finding. Impacts of variant *ALPK2* allele burden between genotypes in the noninfected and HCV monoinfected serogroups were unremarkable (Figure 3A, 3B).

DISCUSSION

This study identified several novel genetic associations among glycogenes and biomarkers of liver fibrosis. Average liver fibrosis scores in the coinfecting serogroup analyzed at baseline were significantly higher than that of either HIV or HCV monoinfected participants as shown in Figure 1, recapitulating the fibrotic trends described in the literature for coinfecting populations [6,26]. Of the 887 nsSNV assessed that either directly (nsSNV affecting NXS/T sequons) or indirectly (nsSNV in glycosylation or lectin genes) alter glycosylation pathways or products, we found seven nsSNV that were associated with an increased risk of hepatic fibrosis among the HIV/HCV coinfecting population. We observed higher APRI and FIB-4 values (indicative of greater fibrosis) in coinfecting participants homozygous for the *ALPK2* rs3809973 minor allele when compared with participants homozygous for the *ALPK2* rs3809973 major allele irrespective of HIV and HCV viral load. As elevations in these viral titers have been correlated with increased liver injury [27], our findings suggest that the genetic risk of hepatic fibrosis among coinfecting individuals carrying the *ALPK2* rs3809973 risk allele is not confounded by viral titers. The lack of association in

coinfecting participants between the *ALPK2* variant heterozygote and increased liver fibrosis suggested the need for variant homozygosity for the detrimental impacts of the variant to manifest in the coinfecting and conforms with a recessive mode of inheritance. As shown in Figure 3, among HIV monoinfected participants, the relative CD4⁺ T-cell percentage among leukocytes was inversely associated with FIB-4. Furthermore, coinfecting participants that were homozygous for the minor allele were significantly increased in terms of fibrosis risk when compared to HCV monoinfected participants of the same genotype; suggesting a need for general HIV-associated immunosuppression to produce the detrimental fibrosis risk increase. Our comparisons of *ALPK2* rs3809973 among serogroups at baseline therefore leads us to speculate that the risk allele's impact on liver fibrosis is reliant on both HCV-mediated liver damage and its perpetuation by HIV-mediated immunosuppression.

The *ALPK2* gene and rs3809973 have not been linked to a pathological liver phenotype to date. Although the association of *ALPK2* rs3809973 with fibrosis in the setting of HIV/HCV coinfection warrants replication, some circumstantial evidence suggests a potential role for *ALPK2* in risk for viral hepatic fibrosis. Hepatic Stellate cells (HSC) lining the perisinusoidal space of the liver are the fibrogenic cell type responsible for extracellular matrix deposition and subsequent fibrosis in the setting of hepatic inflammation. Although this fibrogenic response is designed to protect against liver injury and typically reverses after the hepatic insult subsides, progressive inflammation and the chronic activation of HSCs can lead to cirrhosis and an increased risk of developing hepatocellular carcinoma [28,29]. Signaling molecules and pathways

involved in HSC activation have been described, but most notable is the expression of toll-like receptors on HSCs enables their activation upon exposure to structurally conserved microbial-derived products such as lipopolysaccharide [30]. Although incompletely characterized, the *ALPK2* protein was first identified in cardiomyocytes as an integral regulator of heart development [31]. However, most studies of *ALPK2* have focused on the pathological processes of the gastrointestinal tract. *ALPK2* is associated with luminal apoptosis in colorectal cancer cell lines [32]. Luminal shedding is a phenomenon of the enteric innate immune system designed to maintain the function of the gut barrier by preventing the invasion of virulent microbes into systemic circulation. The increased apoptosis of enterocytes in the absence of their concomitant replacement can yield an increasingly permeable intestinal membrane that leaves the host vulnerable to augmented translocation of microbial products [33]. Since increased microbial translocation is a hallmark of HIV infection and lipopolysaccharide activates HSCs [34], any augmentation of this translocation process would exacerbate liver fibrosis in the context of existing hepatitis. In addition, a genome-wide association study of inflammatory bowel disease, a condition in which pathological epithelial shedding is observed, found the mRNA of *ALPK2* to be up-regulated in inflamed mucosa compared to control samples [35]. Therefore, we speculate that *ALPK2* rs3809973 could enhance liver fibrosis by interfering with enteric immunity. Even though this variant generates a novel NxS/T sequon, augmentation of glycan attachment onto the amino acid substitution encoded by the minor allele has not been demonstrated. Structural studies indicate that the variant does not interrupt the kinase domain nor any residues known to be post-translationally modified, glycosylation or otherwise [31,36]. Therefore, the

282 impact of the K829N substitution encoded by *rs3809973* on ALPK2 structure and
283 function warrant investigation.

284 Although the low minor allele frequency of the remaining 6 nsSNV associated with
285 increased liver fibrosis (i.e., *CCR7* rs2228015, *GLT8D2* rs17035120, *MAN2A2*
286 rs52828316, *MBL2* rs1800450, *MCOLN2* rs77452813, and *TGFB1* rs1800472)
287 precluded detailed modeling, their previous associations with liver disease, metabolism,
288 and viral immunity in other literature provide impetus for further investigation. *TGFB1*
289 has long been linked to enhanced hepatocyte destruction and HSC activation [37].
290 *GLT8D2* and *MAN2A2* have been implicated in non-alcoholic fatty liver disease [38] and
291 coinfecting liver disease [39], respectively. Finally, *CCR7*, *MBL2*, and *MCOLN2* have all
292 been connected to the modulation of host cellular and immune responses in viral
293 infection [40-42]. Taken together, all seven nsSNV and their cognate genes have
294 plausible roles in liver disease pathology and warrant replication in an independent
295 sample(s).

296 We note that there are limitations to this study. As this is an exclusively female cohort,
297 future studies should aim to validate these findings in men. Although we identified that
298 there are potentially more than 42,000 nsSNV that either directly altered N-linked
299 glycosylation sites (NxS/T) or that may indirectly alter the function of enzymes or lectins
300 interacting with glycoproteins, only a subset (2.5%) were available for analysis in the
301 cohort due to a combination of low nsSNV allele frequency in the population and/or lack
302 of inclusion of the majority of nsSNV on the commercial array used. A number of factors

hindered our attempts at a longitudinal assessment of the genetic risk factors on the
 coinfecting population. For one, as the standard of care for HIV treatment changed for
 coinfecting WIHS participants longitudinally (Supplemental Figure 2A, 2B), adjusting for
 shifting antiviral treatment regimens at different time points to meet this standard of care
 was a challenge. Secondly, as this cohort was initially designed to investigate HIV
 progression, the HCV virologic status was only determined at baseline and HCV
 clearance was not assessed further, thereby making longitudinal analyses of HCV-
 infection status susceptible to misclassification bias. Along similar lines, survival bias
 and the availability of more effective and less toxic HIV treatments for new enrollees
 over time in WIHS may have attenuated the relationship between susceptibility alleles
 and fibrosis [27]. The rate of loss to follow-up was also problematic in that nearly one
 third of the coinfecting participants at baseline were no longer in the cohort after four
 visits (2 years) (Supplemental Figure 2C, 2D). Finally, APRI and FIB-4 scores are
 correlated with liver fibrosis risk, but both are imperfect surrogate measures. The utility
 of these surrogate fibrosis metrics has been validated against biopsy and other
 measures (i.e. transient elastography) in previous studies [43], but were not validated by
 such methods at present.

Given the goal of improving the prognosis of liver disease in the HIV/HCV coinfecting
 population, we have identified candidate genes that may participate in hepatic fibrosis.
 Although these genetic associations require replication, demonstration of the impact of
 each of the seven nsSNVs on N-linked glycosylation of the site and its cognate protein
 warrants investigation. Longitudinal HCV testing and assessment of viremia along with

325 additional studies in other HIV/HCV coinfecting cohorts may permit better stratification of
326 serogroups and to perform longitudinal analysis of these candidate gene nsSNV.

ACKNOWLEDGEMENTS

Data in this manuscript were collected by the Women's Interagency HIV Study, now the MACS/WIHS Combined Cohort Study (MWCCS). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). MWCCS (Principal Investigators): Atlanta CRS (Ighovwerha Ofotokun, Anandi Sheth, and Gina Wingood), U01-HL146241; Bronx CRS (Kathryn Anastos and Anjali Sharma), U01-HL146204; Brooklyn CRS (Deborah Gustafson and Tracey Wilson), U01-HL146202; Data Analysis and Coordination Center (Gypsyamber D'Souza, Stephen Gange and Elizabeth Golub), U01-HL146193; Chicago-Cook County CRS (Mardge Cohen and Audrey French), U01-HL146245; Connie Wofsy Women's HIV Study, Northern California CRS (Bradley Aouizerat and Phyllis Tien), U01-HL146242; Metropolitan Washington CRS (Seble Kassaye and Daniel Merenstein), U01-HL146205; Miami CRS (Maria Alcaide, Margaret Fischl, and Deborah Jones), U01-HL146203; UAB-MS CRS (Mirjam-Colette Kempf and Deborah Konkle-Parker), U01-HL146192; UNC CRS (Adaora Adimora), U01-HL146194. The MWCCS is funded primarily by the National Heart, Lung, and Blood Institute (NHLBI), with additional co-funding from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Human Genome Research Institute (NHGRI), National Institute On Aging (NIA), National Institute Of Dental & Craniofacial Research (NIDCR), National Institute Of Allergy And Infectious Diseases (NIAID),

National Institute Of Neurological Disorders And Stroke (NINDS), National Institute Of Mental Health (NIMH), National Institute On Drug Abuse (NIDA), National Institute of Nursing Research (NINR), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). MWCCS data collection is also supported by UL1-TR000004 (UCSF CTSA), P30-AI-050409 (Atlanta CFAR), P30-AI-050410 (UNC CFAR), and P30-AI-027767 (UAB CFAR). Additionally, the authors would like to thank Jing Wu and Yiwen Wang for their data assembly and analysis efforts.

REFERENCES:

1. Sherman KE, Peters MG, Thomas D. Human immunodeficiency virus and liver disease: A comprehensive update. *Hepatol Commun*. 2017;1(10):987-1001. doi:[10.1002/hep4.1112](https://doi.org/10.1002/hep4.1112)
2. Cahill S, Valadéz R. Growing older with HIV/AIDS: new public health challenges. *Am J Public Health*. 2013;103(3):e7-e15. doi:[10.2105/AJPH.2012.301161](https://doi.org/10.2105/AJPH.2012.301161)
3. Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. *J Acquir Immune Defic Syndr*. 2006;43(1):27-34. doi:[10.1097/01.qai.0000233310.90484.16](https://doi.org/10.1097/01.qai.0000233310.90484.16)
4. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. *J Hepatol*. 2005;42(6):799-805. doi:[10.1016/j.jhep.2005.01.022](https://doi.org/10.1016/j.jhep.2005.01.022)

5. Avihingsanon A, Jitmitraparp S, Tangkijvanich P, et al. Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels. *J Gastroenterol Hepatol*. 2014;29(9):1706-1714. doi:[10.1111/jgh.12613](https://doi.org/10.1111/jgh.12613)
6. Chrysanthidis T, Loli G, Metallidis S, Germanidis G. Mechanisms of accelerated liver fibrosis in HIV-HCV coinfection. *AIDS Rev*. 2017;19(3):148-155.
7. Lledó GM, Carrasco I, Benítez-Gutiérrez LM, et al. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. *AIDS*. 2018;32(16):2347-2352.
doi:[10.1097/QAD.0000000000001966](https://doi.org/10.1097/QAD.0000000000001966)
8. Henry B. Drug Pricing & Challenges to Hepatitis C Treatment Access. *J Health Biomed Law*. 2018;14:265-283.
9. Schwarz F, Aepli M. Mechanisms and principles of N-linked protein glycosylation. *Curr Opin Struct Biol*. 2011;21(5):576-582. doi:[10.1016/j.sbi.2011.08.005](https://doi.org/10.1016/j.sbi.2011.08.005)
10. Rudd PM. Glycosylation and the Immune System. *Science*. 2001;291(5512):2370-2376. doi:[10.1126/science.291.5512.2370](https://doi.org/10.1126/science.291.5512.2370)
11. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. *Nat Rev Immunol*. 2007;7(4):255-266. doi:[10.1038/nri2056](https://doi.org/10.1038/nri2056)
12. Van Breedam W, Pöhlmann S, Favoreel HW, de Groot RJ, Nauwynck HJ. Bitter-sweet symphony: glycan-lectin interactions in virus biology. *FEMS Microbiol Rev*. 2014;38(4):598-632. doi:[10.1111/1574-6976.12052](https://doi.org/10.1111/1574-6976.12052)

13. Mazumder R, Morampudi KS, Motwani M, Vasudevan S, Goldman R. Proteome-Wide Analysis of Single-Nucleotide Variations in the N-Glycosylation Sequon of Human Genes. Dalby AR, ed. *PLoS ONE*. 2012;7(5):e36212.
doi:[10.1371/journal.pone.0036212](https://doi.org/10.1371/journal.pone.0036212)
14. **Fan Y, Hu Y**, Yan C, et al. Loss and gain of N-linked glycosylation sequons due to single-nucleotide variation in cancer. *Sci Rep*. 2018;8(1):4322.
doi:[10.1038/s41598-018-22345-2](https://doi.org/10.1038/s41598-018-22345-2)
15. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. *Clin Diagn Lab Immunol*. 2005;12(9):1013-1019. doi:[10.1128/CDLI.12.9.1013-1019.2005](https://doi.org/10.1128/CDLI.12.9.1013-1019.2005)
16. Sarkar M, Aouzierat B, Bacchetti P, et al. Association of IFNL3 and IFNL4 polymorphisms with liver-related mortality in a multiracial cohort of HIV/HCV-coinfected women. *J Viral Hepat*. 2015;22(12):1055-1060. doi:[10.1111/jvh.12431](https://doi.org/10.1111/jvh.12431)
17. French AL, Martin JW, Evans CT, et al. Macrophage Activation and the Tumor Necrosis Factor Cascade in Hepatitis C Disease Progression Among HIV-Infected Women Participating in the Women's Interagency HIV Study. *J Acquir Immune Defic Syndr*. 2017;76(4):438-444. doi:[10.1097/QAI.0000000000001524](https://doi.org/10.1097/QAI.0000000000001524)
18. Urabe Y, Ochi H, Kato N, et al. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. *J Hepatol*. 2013;58(5):875-882.
doi:[10.1016/j.jhep.2012.12.024](https://doi.org/10.1016/j.jhep.2012.12.024)

19. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*. 2006;43(6):1317-1325. doi:[10.1002/hep.21178](https://doi.org/10.1002/hep.21178)
20. Lin Z-H, Xin Y-N, Dong Q-J, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. *Hepatology*. 2011;53(3):726-736. doi:[10.1002/hep.24105](https://doi.org/10.1002/hep.24105)
21. Kuniholm MH, Gao X, Xue X, et al. The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women. *J Infect Dis*. 2011;203(12):1807-1814. doi:[10.1093/infdis/jir192](https://doi.org/10.1093/infdis/jir192)
22. Hansen L, Lind-Thomsen A, Joshi HJ, et al. A glycogene mutation map for discovery of diseases of glycosylation. *Glycobiology*. 2015;25(2):211-224. doi:[10.1093/glycob/cwu104](https://doi.org/10.1093/glycob/cwu104)
23. Bouwman LH, Roos A, Terpstra OT, et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. *Gastroenterology*. 2005;129(2):408-414. doi:[10.1016/j.gastro.2005.06.049](https://doi.org/10.1016/j.gastro.2005.06.049)
24. Shendre A, Wiener HW, Irvin MR, et al. Genome-wide admixture and association study of subclinical atherosclerosis in the Women's Interagency HIV Study (WIHS). *PLoS ONE*. 2017;12(12):e0188725. doi:[10.1371/journal.pone.0188725](https://doi.org/10.1371/journal.pone.0188725)
25. Frasco MA, Mack WJ, Van Den Berg D, et al. Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine. *AIDS*. 2012;26(16):2097-2106. doi:[10.1097/QAD.0b013e3283593602](https://doi.org/10.1097/QAD.0b013e3283593602)

26. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. *Gut*. 2003;52(7):1035-1040. doi:[10.1136/gut.52.7.1035](https://doi.org/10.1136/gut.52.7.1035)
27. Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. *J Hepatol*. 2006;44(1):47-55. doi:[10.1016/j.jhep.2005.07.006](https://doi.org/10.1016/j.jhep.2005.07.006)
28. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. *Gut*. 2015;64(5):830-841. doi:[10.1136/gutjnl-2014-306842](https://doi.org/10.1136/gutjnl-2014-306842)
29. O'Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. *World J Gastroenterol*. 2018;24(39):4436-4447. doi:[10.3748/wjg.v24.i39.4436](https://doi.org/10.3748/wjg.v24.i39.4436)
30. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. *Nat Rev Gastroenterol Hepatol*. 2017;14(7):397-411. doi:[10.1038/nrgastro.2017.38](https://doi.org/10.1038/nrgastro.2017.38)
31. Ryazanov AG, Pavur KS, Dorovkov MV. Alpha-kinases: a new class of protein kinases with a novel catalytic domain. *Curr Biol*. 1999;9(2):R43-45. doi:[10.1016/s0960-9822\(99\)80006-2](https://doi.org/10.1016/s0960-9822(99)80006-2)
32. Yoshida Y, Tsunoda T, Doi K, et al. ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model. *Anticancer Res*. 2012;32(6):2301-2308.
33. Yu LC-H, Wang J-T, Wei S-C, Ni Y-H. Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathology. *World J Gastrointest Pathophysiol*. 2012;3(1):27-43. doi:[10.4291/wjgp.v3.i1.27](https://doi.org/10.4291/wjgp.v3.i1.27)

34. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med*. 2006;12(12):1365-1371. doi:[10.1038/nm1511](https://doi.org/10.1038/nm1511)
35. Palmieri O, Creanza TM, Bossa F, et al. Genome-wide Pathway Analysis Using Gene Expression Data of Colonic Mucosa in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2015;21(6):1260-1268. doi:[10.1097/MIB.0000000000000370](https://doi.org/10.1097/MIB.0000000000000370)
36. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. *Nucleic Acids Res*. 2015;43(Database issue):D512-520. doi:[10.1093/nar/gku1267](https://doi.org/10.1093/nar/gku1267)
37. Dooley S, ten Dijke P. TGF- β in progression of liver disease. *Cell Tissue Res*. 2012;347(1):245-256. doi:[10.1007/s00441-011-1246-y](https://doi.org/10.1007/s00441-011-1246-y)
38. Zhan Y, Zhao F, Xie P, et al. Mechanism of the effect of glycosyltransferase GLT8D2 on fatty liver. *Lipids Health Dis*. 2015;14:43. doi:[10.1186/s12944-015-0040-3](https://doi.org/10.1186/s12944-015-0040-3)
39. Gupta P, Liu B, Wu JQ, et al. Genome-wide mRNA and miRNA analysis of peripheral blood mononuclear cells (PBMC) reveals different miRNAs regulating HIV/HCV co-infection. *Virology*. 2014;450-451:336-349. doi:[10.1016/j.virol.2013.12.026](https://doi.org/10.1016/j.virol.2013.12.026)
40. Hayasaka H, Kobayashi D, Yoshimura H, Nakayama EE, Shioda T, Miyasaka M. The HIV-1 Gp120/CXCR4 axis promotes CCR7 ligand-dependent CD4 T cell migration: CCR7 homo- and CCR7/CXCR4 hetero-oligomer formation as a

possible mechanism for up-regulation of functional CCR7. *PLoS ONE*.

2015;10(2):e0117454. doi:[10.1371/journal.pone.0117454](https://doi.org/10.1371/journal.pone.0117454)

41. Eisen S, Dzwonek A, Klein NJ. Mannose-binding lectin in HIV infection. *Future*

Virol. 2008;3(3):225-233. doi:[10.2217/17460794.3.3.225](https://doi.org/10.2217/17460794.3.3.225)

42. Rinkenberger N, Schoggins JW. Mucolipin-2 Cation Channel Increases

Trafficking Efficiency of Endocytosed Viruses. *mBio*. 2018;9(1).

doi:[10.1128/mBio.02314-17](https://doi.org/10.1128/mBio.02314-17)

43. Papadopoulos N, Vasileiadi S, Papavdi M, et al. Liver fibrosis staging with

combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an

alternative to transient elastography. *Ann Gastroenterol.* 2019;32(5):498-503.

doi:[10.20524/aog.2019.0406](https://doi.org/10.20524/aog.2019.0406)

Author names in bold designate shared co-first authorship.

SUPPLEMENTAL FIGURES AND FIGURE LEGENDS:

Supplemental Figure 1. Genotyping and data processing workflow.

Supplemental Figure 2. Longitudinal trends characterizing the HIV/HCV

coinfected population: The values are summarized annually at every second visit.

(A) Composition of the anti-HIV drug regimens changing in line with treatment guidelines; no therapy (red), monotherapy (blue), combination therapy (green), or highly active antiretroviral therapy (HAART) (purple). (B) Mean CD4⁺ percentages (black symbols) and mean HIV viral load (red symbols). (C) The median APRI and (D) FIB-4 indexes.

Supplemental Figure 1. Genotyping and data processing workflow

Supplementary Figure 2. Longitudinal trends characterizing the HIV/HCV coinfecting population